Dr. Fan brings over 20 years of extensive experience in biomedical research and drug development. He is a renowned expert in cancer biology and neurobiology, having published more than 60 peer-reviewed papers in leading international journals and holding over 20 patents. His contributions have been recognized with numerous prestigious awards, including the National Natural Science Award (2002) and the Chinese Medical Science Award (2001). He was also honored as a scholar of the Chinese Academy of Sciences' Hundred Talents Program.

        Dr. Fan earned his MD in Nuclear Medicine from Shanghai Jiao Tong University School of Medicine in 1996. Following his doctoral studies, he completed six years of postdoctoral training at the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, and Vanderbilt University in the United States.

        Prior to founding Immunophage, Dr. Fan held various academic and industry positions. He served as a Lecturer in the Department of Cancer Biology at Vanderbilt University (2001-2002) and later as an Assistant Professor at Vanderbilt University School of Medicine (2004-2008). He also held concurrent appointments as an Assistant Professor in the Department of Biomedical Sciences at Meharry Medical College (2006-2008) and as a Tenured Associate Professor in the Department of Neurobiology and Neurotoxicology at Meharry Medical College. Additionally, he was an Assistant Professor in the Department of Pharmacology and Toxicology at Virginia Commonwealth University School of Medicine (2008-2010).

        From 2010 to 2016, Dr. Fan served as Associate Director at GlaxoSmithKline (Shanghai) R&D Co., Ltd. He then served as Deputy Dean of the School of Translational Medicine and Director of the Biomedical Research Center at Nanchang University from 2016 to 2018.

        Dr. Wang brings over 20 years of comprehensive experience in the global pharmaceutical industry, with deep expertise in drug discovery and product development. As Chief Scientific Officer, he oversees all aspects of our Group's research strategy and pipeline advancement.

        Dr. Wang earned his Bachelor of Science in Veterinary Medicine from Nanjing Agricultural University in July 1988. He completed his postdoctoral residency in Laboratory Animal Medicine at the University of Pennsylvania in July 1998, followed by a PhD in Tissue Injury and Repair from the University of Calgary in June 2003. He then pursued a postdoctoral fellowship in Rheumatoid Arthritis at Harvard Medical School, which he completed in March 2005.

        Prior to joining Immunophage, Dr. Wang held academic and industry leadership positions. He served as a Research Associate in Abnormal Wound Healing (2005-2007) and later as an Assistant Professor in the Division of Plastic Surgery, Department of Surgery, Faculty of Medicine & Dentistry at the University of Alberta (2007-2010). From 2009 to 2018, he worked at GlaxoSmithKline (Shanghai) R&D Co., Ltd., where he rose to Director of the Integrated Bioscience Platform Department. He then served as Senior Vice President at Hangzhou Qihan Bio Inc. from May 2018 to January 2019.

        Dr. Wang has been recognized as a Senior Laboratory Animal Veterinarian by the China Laboratory Animal Association since August 2019 and was nominated as an Entrepreneurship and Innovation Talent of Jiangsu Province in 2022.

        Ms. Tao is an Executive Director, Vice President, Board Secretary and Joint Company Secretary of Immunophage. She joined our Group on April 23, 2020, was appointed Vice President and Board Secretary in October 2024, became a Director in April 2021, and was re-designated as an Executive Director on September 26, 2025. She also serves as a member of the Remuneration Committee.

        Ms. Tao brings over 20 years of extensive experience in capital operations, human resources management, and corporate governance. She is primarily responsible for overseeing our Group's financial affairs, capital operations, human resources, administration, environmental health and safety (EHS), and board secretarial functions, and serves as the principal financial officer of the Company.

        Prior to joining Immunophage, Ms. Tao served as Assistant Human Resources Manager at Shanghai SLAC Laboratory Animal Co., Ltd. from August 2004 to April 2020. She earned her Master of Public Administration degree from Shanghai Normal University in January 2015.

        Dr. Liu is a leading expert in neurodegenerative diseases with over 15 years of dedicated research experience. As Supervisor and Head of the Neurology & Business Department, she plays a pivotal role in overseeing preclinical pharmacology and efficacy studies for our neuroscience pipeline.

        Dr. Liu earned her PhD from the Institute of Neuroscience, Chinese Academy of Sciences. Following her doctoral studies, she completed three years of postdoctoral training at the Shanghai Institutes for Biological Sciences. Before joining Immunophage, she served as a Professor at Guangxi Medical University for four years, where she led multiple research projects.

        Her outstanding research contributions have been recognized with two grants from the National Natural Science Foundation of China.

        Dr. Wang brings 15 years of proven drug discovery experience across leading pharmaceutical and CRO organizations including ChemPartner, MediChem, and Otsuka Pharmaceuticals. He specializes in advancing preclinical candidates through strategic medicinal chemistry and translational science.

        His core expertise spans hit-to-lead optimization, cost-efficient process development, and resolving ADME/toxicity challenges in oncology, central nervous system (CNS), and metabolic disease pipelines. Dr. Wang's integrated approach to drug discovery—from hit validation through preclinical candidate nomination—consistently accelerates pipeline advancement by strategically addressing complex translational barriers.

        Mr. Li is an Executive Director and Head of the Biology Platform at Immunophage. He joined our Group as a Pharmacology Researcher in February 2019, was promoted to Associate Director of the Department of Disease Research and Drug Discovery (2022-2024), and assumed his current role in August 2024. He was appointed a Director on August 12, 2024, and re-designated as an Executive Director on September 26, 2025.

        Mr. Li is primarily responsible for project R&D, program management, departmental operations, external technical collaborations, and intellectual property protection. He brings extensive experience in pharmaceutical research and development.

        Prior to joining Immunophage, Mr. Li worked as an Intern Researcher at the Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences (formerly the Institute Pasteur of Shanghai) from August 2017 to April 2018. He then served as a Scientific Research Assistant at the Life Sciences Institute, Zhejiang University from May 2018 to February 2019, where he managed laboratory operations and research projects.

        Mr. Li earned his Bachelor of Science in Biotechnology from Northwest A&F University in July 2014 and his Master of Science in Biochemistry and Molecular Biology from Shanghai University in July 2017.

        Dr. Huang brings over 20 years of global clinical development experience leading Phase I to Phase IV trials and NDA applications across multiple therapeutic areas, including autoimmune diseases, solid tumors, CNS disorders, cardiometabolic conditions, and infectious diseases.

        He has successfully delivered more than 30 global and China-based clinical trials, including 18+ non-oncology and 12+ oncology studies, and has managed teams of over 100 Clinical Research Coordinators (CRCs) and 10+ Clinical Research Associates (CRAs) for multinational pharmaceutical companies. His expertise covers Investigator-Initiated Trials (IITs), all phases of clinical development, and registration studies.

        Ms. Wang brings 16 years of specialized expertise in new drug R&D project management and regulatory affairs, with comprehensive knowledge of global drug development and registration processes. She joined our group in 2024 and was appointed as Associate Director in 2026.

        She has built a distinguished career working with leading CROs and biotech companies, successfully leading over 10 projects across oncology, autoimmune diseases, and CNS disorders. She has guided these programs through the entire R&D and regulatory lifecycle, advancing them into Phase I and Phase II clinical trials.

        Ms. Wang earned her Master's degree in Biomedicine from East China Normal University.

        Mr. Hao brings extensive experience in marketing and business development across immunology, dermatology, cardiovascular disease (CVD), CNS, and oncology. He holds a Master of Public Health degree from the University of Hong Kong. He joined our group in 2025 and was appointed as Associate Director in 2026.

        He has established a strong professional network with multinational corporations (MNCs), big pharma, and biotech companies worldwide. His core competencies include R&D strategy, marketing, strategic planning, and deal structuring, with exceptional English communication skills that enable effective global collaboration. He possesses deep expertise in in-licensing and out-licensing transactions, having successfully executed multiple strategic partnerships and asset deals throughout his career.